Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 7

Second-Line LR- MDS Setting: Treatment Options and Considerations

,

Panelists discuss how they determine thresholds for changing therapy in patients with MDS, evaluate second-line treatment options including the potential use of ESAs after luspatercept, and offer key takeaways for community colleagues managing similar clinical scenarios.

Video content above is prompted by the following:

  • What is your threshold for changing therapy in your clinical practice?
  • What treatment options would you consider in the second-line setting for this patient? Do you consider trialing ESAs post luspatercept?
  • What are some key takeaways you can offer community colleagues from this clinical scenario and discussion?